These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 1280751)

  • 1. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
    Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
    Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes.
    Alexandrakis M; Coulocheri S; Xylouri I; Ganotakis E; Eliakis P; Karkavitsas N; Eliopoulos GD
    Haematologia (Budap); 1998; 29(1):13-24. PubMed ID: 9704253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous stem cell transplantation: sequential production of hematopoietic cytokines underlying granulocyte recovery.
    Baiocchi G; Scambia G; Benedetti P; Menichella G; Testa U; Pierelli L; Martucci R; Foddai ML; Bizzi B; Mancuso S
    Cancer Res; 1993 Mar; 53(6):1297-303. PubMed ID: 7680283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3.
    Maurer AB; Ganser A; Buhl R; Seipelt G; Ottmann OG; Mentzel U; Geissler RG; Hoelzer D
    Leukemia; 1993 Nov; 7(11):1728-33. PubMed ID: 8231242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.
    Musto P; Matera R; Minervini MM; Checchia-de Ambrosio C; Bodenizza C; Falcone A; Carotenuto M
    Haematologica; 1994; 79(3):265-8. PubMed ID: 7926977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
    Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
    Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
    Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
    Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
    Asano H; Hotta T; Ichihara M; Murate T; Kobayashi M; Saito H
    Leukemia; 1994 May; 8(5):833-8. PubMed ID: 7514249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pattern of blood levels of erythropoietin and proinflammatory cytokines in patients with anemia of chronic disorders secondary to infection].
    Poveda Gómez F; Camacho Siles J; Quevedo Morales E; Fernández Zamorano A; Codoceo Alquinta R; Arnalich Fernández F; Sempere Alcocer M
    An Med Interna; 2001 Jun; 18(6):298-304. PubMed ID: 11503575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte and granulocyte-macrophage colony-stimulating factors, their receptors and interleukin-3 levels in newborns.
    Coşkun M; Kardelen F; Oygür N; Undar L; Savaş A; Yeğin O
    Turk J Pediatr; 1997; 39(3):295-301. PubMed ID: 9339107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of tumor necrosis factor-alpha and interferon-gamma on erythropoietin production and erythropoiesis in cancer patients with anemia].
    Wang W; Zhang MH; Yu Y; Xu CG
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):681-4. PubMed ID: 18399174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase.
    Balleari E; Bason C; Visani G; Gobbi M; Ottaviani E; Ghio R
    Haematologica; 1994; 79(1):7-12. PubMed ID: 15378942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome.
    Dalamaga M; Karmaniolas K; Chamberland J; Nikolaidou A; Lekka A; Dionyssiou-Asteriou A; Mantzoros CS
    Metabolism; 2013 Dec; 62(12):1830-9. PubMed ID: 24140093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome.
    Stasi R; Brunetti M; Bussa S; Conforti M; Martin LS; La Presa M; Bianchi M; Parma A; Pagano A
    Clin Lab Haematol; 1997 Sep; 19(3):197-201. PubMed ID: 9352145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous serum levels and surface receptor expression of GM-CSF and IL-3 in patients with myelodysplastic syndromes.
    Zwierzina H; Schöllenberger S; Herold M; Schmalzl F; Besemer J
    Leuk Res; 1992 Dec; 16(12):1181-6. PubMed ID: 1465026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
    Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
    Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased levels of circulating cytokines in patients with untreated Hodgkin's disease.
    Gause A; Keymis S; Scholz R; Schobert I; Jung W; Diehl V; Pohl C; Pfreundschuh M
    Lymphokine Cytokine Res; 1992 Apr; 11(2):109-13. PubMed ID: 1581417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of soluble forms of ICAM and VCAM in patients with myelodysplastic syndromes and their prognostic significance.
    Passam FH; Tsirakis G; Boula A; Fragou A; Consolas I; Alegakis A; Kyriakou DS; Alexandrakis MG
    Clin Lab Haematol; 2004 Dec; 26(6):391-5. PubMed ID: 15595996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.